Molecules (Jan 2022)

PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs

  • Nikolay Kuzmich,
  • Elena Andresyuk,
  • Yuri Porozov,
  • Vadim Tarasov,
  • Mikhail Samsonov,
  • Nina Preferanskaya,
  • Valery Veselov,
  • Renad Alyautdin

DOI
https://doi.org/10.3390/molecules27020434
Journal volume & issue
Vol. 27, no. 2
p. 434

Abstract

Read online

PCSK9 has now become an important target to create new classes of lipid-lowering drugs. The prevention of its interaction with LDL receptors allows an increase in the number of these receptors on the surface of the cell membrane of hepatocytes, which leads to an increase in the uptake of cholesterol-rich atherogenic LDL from the bloodstream. The PCSK9 antagonists described in this review belong to different classes of compounds, may have a low molecular weight or belong to macromolecular structures, and also demonstrate different mechanisms of action. The mechanisms of action include preventing the effective binding of PCSK9 to LDLR, stimulating the degradation of PCSK9, and even blocking its transcription or transport to the plasma membrane/cell surface. Although several types of antihyperlipidemic drugs have been introduced on the market and are actively used in clinical practice, they are not without disadvantages, such as well-known side effects (statins) or high costs (monoclonal antibodies). Thus, there is still a need for effective cholesterol-lowering drugs with minimal side effects, preferably orally bioavailable. Low-molecular-weight PCSK9 inhibitors could be a worthy alternative for this purpose.

Keywords